Becton Dickinson
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
82% more funds holding in top 10
Funds holding in top 10: 11 [Q3] → 20 (+9) [Q4]
52% more first-time investments, than exits
New positions opened: 193 | Existing positions closed: 127
16% more call options, than puts
Call options by funds: $320M | Put options by funds: $276M
2% more funds holding
Funds holding: 1,550 [Q3] → 1,586 (+36) [Q4]
1.09% more ownership
Funds ownership: 89.16% [Q3] → 90.25% (+1.09%) [Q4]
3% less capital invested
Capital invested by funds: $62.3B [Q3] → $60.5B (-$1.79B) [Q4]
16% less repeat investments, than reductions
Existing positions increased: 532 | Existing positions reduced: 635
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$279
23%
upside
Avg. target
$280
23%
upside
High target
$280
23%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Barclays Travis Steed 33% 1-year accuracy 2 / 6 met price target | 23%upside $279 | Overweight Maintained | 14 Feb 2025 |
Piper Sandler Jason Bednar 35% 1-year accuracy 13 / 37 met price target | 23%upside $280 | Overweight Maintained | 28 Jan 2025 |
Financial journalist opinion
Based on 13 articles about BDX published over the past 30 days
Positive
Seeking Alpha
6 hours ago
Becton Dickinson Could Be Cure To Demand For Medtech Supplies, With Robust Pipeline
Becton Dickinson gets rating buy in my first coverage of this stock. Macro demand for medtech and surgical supplies could favor this globally diversified firm with an active portfolio and growth pipeline. The firm is a proven dividend grower and cashflow generator with low debt/equity and investment-grade credit ratings.
Neutral
PRNewsWire
3 days ago
BD Names Gregory J. Hayes to Board of Directors
FRANKLIN LAKES, N.J. , March 27, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Gregory J.
Negative
Investors Business Daily
3 days ago
How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain
Tariff uncertainty has cast a pall over medical stocks. Re-shoring is possible, but expensive, leaving them in a "wait-and-see" pattern.
Negative
Zacks Investment Research
4 days ago
BDX Stock Declines Following Class I Classification for Alaris Recall
BD's recall of Alaris infusion pumps following software issues has been classified as the most severe recall by the FDA. A suspension of sales may hurt the top line going forward.
Positive
Zacks Investment Research
6 days ago
BDX Shares May Climb as GalaFLEX LITE Trial Hits Key Milestone
BD advances its clinical trial for the bioabsorbable GalaFLEX LITE scaffold, aiming to improve outcomes in breast implant revision surgeries and patient recovery.
Positive
Seeking Alpha
1 week ago
2025 Dividend Kings: Strong Run Continues
The Dividend Kings are outperforming the S&P 500 in 2025 by 4.57%. Top performers include National Fuel & Gas (+30.21%), Consolidated Edison (+22.66%), and AbbVie (+20.40%). Promising Dividend Kings identified in February showed relative outperformance, averaging -0.38% vs. -1.58% for all Kings and -3.34% for SPY.
Positive
Zacks Investment Research
1 week ago
Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Neutral
PRNewsWire
1 week ago
BD Announces Milestone in Clinical Trial for Use of Bioabsorbable GalaFLEX LITE™ Scaffold in Breast Implant Revision Surgery
FRANKLIN LAKES, N.J. , March 20, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the first patient treated in an Investigational Device Exemption (IDE) clinical trial intended to advance BD's efforts to achieve Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the use of GalaFLEX LITE™ Scaffold in decreasing capsular contracture (CC) recurrence during breast revision surgery.
Positive
Zacks Investment Research
1 week ago
Here's Why Becton Dickinson (BDX) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Positive
Zacks Investment Research
1 week ago
Here's Why Becton Dickinson (BDX) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Charts implemented using Lightweight Charts™